Literature DB >> 11786506

Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta.

C L M Silva1, F Noël, E J Barreiro.   

Abstract

. The effects of LASSBio 294, a new 3,4-methylenedioxybenzoyl-2-thienylhydrazone, on vascular tonus were investigated in isolated rat aortic rings. 2. LASSBio 294 induced a concentration-dependent relaxation of intact rat aortic rings with an inhibitory concentration (IC(50)) of 74 microM (95% confidence limits: 59 - 92). The mechanical removal of the endothelium abolished this effect. 3. In aortic rings with intact endothelium the effect of 100 microM LASSBio 294 was not altered by the pharmacological inhibition of NOS and cyclo-oxygenase pathways with 500 microM L-NAME and 10 microM indomethacin, respectively. 4. LASSBio 294 (100 microM) was able to relax aortic rings pre-contracted with high extracellular K(+) (KCl 100 mM). 5. The relaxant effect of LASSBio 294 was fully reversed (and prevented) by the addition of 1 microM ODQ (1H-(1,2,4)oxadiazolo[4,3-a]quinoxaline-1-one), a selective inhibitor of soluble guanylate cyclase. 6. LASSBio 294 (100 microM) had no direct effect on PDE3 and PDE4 activities, however, it increased by 150% cyclic GMP content in aortic rings pre-treated with 100 microM L-NAME and 10 microM indomethacin, as did 1 microM zaprinast, a selective PDE5 inhibitor. 7. In conclusion, LASSBio 294 induced relaxation of isolated rat aorta probably by directly increasing cyclic GMP content, possibly as a consequence of PDE5 inhibition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786506      PMCID: PMC1573130          DOI: 10.1038/sj.bjp.0704473

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Design and synthesis of novel potent antinociceptive agents: methyl-imidazolyl N-acylhydrazone derivatives.

Authors:  J M Figueiredo; C A Câmara; E G Amarante; A L Miranda; F M Santos; C R Rodrigues; C A Fraga; E J Barreiro
Journal:  Bioorg Med Chem       Date:  2000-09       Impact factor: 3.641

Review 2.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

3.  Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism.

Authors:  H Y Kwan; Y Huang; X Yao
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Species-dependent differences in the properties of particulate cyclic nucleotide phosphodiesterase from rat and rabbit ventricular myocardium.

Authors:  M Shahid; M Wilson; C D Nicholson; R J Marshall
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

Review 6.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

7.  Endothelium-derived hyperpolarizing factor but not NO reduces smooth muscle Ca2+ during acetylcholine-induced dilation of microvessels.

Authors:  S S Bolz; C de Wit; U Pohl
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

8.  Potassium channel-mediated relaxation to acetylcholine in rabbit arteries.

Authors:  C L Cowan; J J Palacino; S Najibi; R A Cohen
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

9.  Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.

Authors:  D de Cheffoy de Courcelles; K de Loore; E Freyne; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

10.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle.

Authors:  V M Bolotina; S Najibi; J J Palacino; P J Pagano; R A Cohen
Journal:  Nature       Date:  1994-04-28       Impact factor: 49.962

View more
  6 in total

1.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

2.  N-substituted indole carbohydrazide derivatives: synthesis and evaluation of their antiplatelet aggregation activity.

Authors:  Seyedeh Sara Mirfazli; Farzad Kobarfard; Loghman Firoozpour; Ali Asadipour; Marjan Esfahanizadeh; Kimia Tabib; Abbas Shafiee; Alireza Foroumadi
Journal:  Daru       Date:  2014-09-20       Impact factor: 3.117

Review 3.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

4.  LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A2A Receptor.

Authors:  Vinicius F Carvalho; Tatiana P T Ferreira; Ana C S de Arantes; François Noël; Roberta Tesch; Carlos M R Sant'Anna; Eliezer J L Barreiro; Carlos A M Fraga; Patrícia M Rodrigues E Silva; Marco A Martins
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

5.  Effect of S-Se Bioisosteric Exchange on Affinity and Intrinsic Efficacy of Novel N-acylhydrazone Derivatives at the Adenosine A2A Receptor.

Authors:  Júlia Galvez Bulhões Pedreira; Rafaela Ribeiro Silva; François G Noël; Eliezer J Barreiro
Journal:  Molecules       Date:  2021-12-04       Impact factor: 4.411

6.  Impairment of locomotor activity induced by the novel N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice.

Authors:  G A P Silva; A E Kummerle; F Antunes; C A M Fraga; E J Barreiro; G Zapata-Sudo; R T Sudo
Journal:  Braz J Med Biol Res       Date:  2013-03-19       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.